Penumbra stock reports 14.9 percent revenue growth

Penumbra stock stood at USD 319.44 on the NYSE on September 23, 2026, after a USD 0.05 daily gain. The medical-device company reported Q2 2026 revenue of USD 390.05 million, with growth offset by a clear earnings miss.

Revenue grows across segments

According to Zacks on September 23, 2026, Q2 2026 revenue rose 14.9 percent year over year. Thrombectomy revenue increased 12.5 percent, while Embolization and Access revenue advanced 20.0 percent.

The segment split matters because the faster-growing business line is expanding at a wider rate than the overall company. International revenue rose 7.6 percent in Q2 2026, and international sales represented 21.7 percent of quarterly revenue.

Profit growth trails sales

Yahoo Finance reported that Q2 2026 operating income reached USD 41.0 million, compared with USD 40.8 million a year earlier. Operating margin fell to 10.5 percent from 12.0 percent, while SG&A climbed 24.1 percent against 14.9 percent revenue growth.

The pressure is also visible in per-share earnings. According to MarketBeat on September 14, 2026, Q2 EPS was USD 0.88 against a USD 1.16 consensus, a USD 0.28 miss. Revenue exceeded the USD 389.64 million estimate by USD 0.41 million.

Stock remains below yearly high

Penumbra stock was USD 42.97 below its 52-week high of USD 362.41 on September 23, 2026, a 11.9 percent gap. Its market capitalization was USD 12,582,549,936, while the average analyst price objective cited by MarketBeat was USD 367.07.